MorphoSys AG (MOR)
18.96
0.45 (2.43%)
At close: Aug 02, 2024, 8:00 PM
2.43% (1D)
| Bid | n/a |
| Market Cap | 2.86B |
| Revenue (ttm) | 203.58M |
| Net Income (ttm) | -460.26M |
| EPS (ttm) | -1.5 |
| PE Ratio (ttm) | -12.64 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 19,165 |
| Avg. Volume (20D) | 47,073 |
| Open | 18.38 |
| Previous Close | 18.51 |
| Day's Range | 18.38 - 19.15 |
| 52-Week Range | 4.18 - 19.50 |
| Beta | 0.66 |
About MOR
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2018
Employees 464
Stock Exchange NASDAQ
Ticker Symbol MOR
Website https://www.morphosys.com